Dog Immune-Mediated Hemolytic Anemia

Immune-mediated hemolytic anemia (IMHA) is a life-threatening condition in which the immune system destroys red blood cells. Prompt recognition and aggressive treatment are critical for survival and welfare.

Key Facts

IMHA has a mortality rate of 30-70% even with treatment, making it one of the most serious immune diseases in dogs
Common presentations include sudden weakness, pale or yellow gums, rapid breathing, and collapse
Cocker Spaniels, Springer Spaniels, and Poodles are overrepresented, suggesting genetic components
Treatment involves immunosuppressive drugs including prednisone and mycophenolate, often combined
Blood transfusions provide critical support while immunosuppression takes effect but carry their own risks

Welfare Considerations

Acute IMHA is a genuine welfare emergency. Dogs experience rapid deterioration with profound weakness, breathlessness from severe anemia, and the physical distress of a crisis illness. The treatment period is itself stressful - hospitalization, multiple medications, monitoring, and potential transfusions. Survivors face a long recovery with gradual immunosuppressive tapering over months. Relapse is common and each episode is a welfare crisis. Owners need preparation for the emotional and financial demands of IMHA management and honest conversations about prognosis.

What You Can Do

Recognize emergency signs: sudden weakness, pale gums, rapid breathing - seek emergency care immediately
Ask your emergency vet about referral to an internal medicine specialist for IMHA management
Join IMHA dog owner support communities to navigate the complex management protocol
Discuss realistic prognosis and quality of life honestly with your vet throughout treatment